NutriPharma

NutriPharma ASA was a Norwegian biotechnology company that specialized in the development of soy-based pharmaceutical and nutraceutical products for metabolic and cardiovascular health. The company's core technology, Abacor, is a proprietary complex of soy protein, soy fibers, and soy phospholipids designed to lower LDL cholesterol and improve glucose metabolism. NutriPharma achieved significant clinical milestones, including the completion of Phase 3 trials for hypercholesterolemia and Phase 2 trials for type 2 diabetes. Historically listed on the Oslo Stock Exchange, the company was a pioneer in applying pharmaceutical-grade clinical rigor to food-derived bioactive compounds before its eventual acquisition and integration into Natural ASA.